Vimarsana
Biggest News Aggregation in the World

Page 47 - Roivant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roivant Sciences Today - Breaking & Trending Today

Ramaswamy touts youthful, fresh perspective in pitch to NH primary voters - Vimarsana News

Ramaswamy touts youthful, fresh perspective in pitch to NH primary voters

Republican presidential candidate Vivek Ramaswamy paid a visit to Keene Saturday evening where he spoke to voters ahead of New Hampshire's first-in-the-nation primary in January.

Critical Comparison: Immunovant (NASDAQ:IMVT) vs. Ginkgo Bioworks (NYSE:DNA) - Vimarsana News

Critical Comparison: Immunovant (NASDAQ:IMVT) vs. Ginkgo Bioworks (NYSE:DNA)

Immunovant (NASDAQ:IMVT – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Analyst Recommendations This is a breakdown of recent […]

Tech entrepreneur takes presidential campaign to Michigan's 'forgotten cities' - Vimarsana News

Tech entrepreneur takes presidential campaign to Michigan's 'forgotten cities'

Republican presidential candidate Vivek Ramaswamy will be in Michigan on Wednesday as the 2024 primary campaign season continues to ramp up nationwide.

Source: wsbt.com
Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) - Vimarsana News

Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV)

On October 5, 2023, Eric Venker, the COO of Roivant Sciences Ltd (NASDAQ:ROIV), sold 1,200,000 shares of the company.

Source: yahoo.com
Lokavant receives $8 million from investment giant, Mitsui - Vimarsana News

Lokavant receives $8 million from investment giant, Mitsui

Clinical trial platform company, Lokavant, has received an $8 million strategic investment from global trading and investment giant, Mitsui & Co. Ltd.